论文部分内容阅读
Ｗ ｏｒｔｍ ａｎｎｉｎ 是肌醇磷脂３激酶的不可逆抑制剂．用比浊法分析血小板聚集；肌醇磷脂用３２ Ｐ磷酸钠标记，用氯仿和甲醇抽提，用 Ｔ Ｌ Ｃ和放射自显影分析，研究了 Ｗ ｏｒｔｍ ａｎｎｉｎ 对凝血酶诱导的人血小板聚集和磷脂酰肌醇三磷酸（ Ｐ Ｉ Ｐ３）累积的影响．结果显示， Ｗ ｏｒｔｍ ａｎｎｉｎ 对凝血酶（５００ Ｕ／ Ｌ）诱导的人血小板聚集有抑制作用，这种抑制作用在一定范围内呈剂量依赖关系（２０～８０μｍ ｏｌ／ Ｌ）．凝血酶（５００ Ｕ／ Ｌ）诱导人血小板 Ｐ Ｉ Ｐ３ 的累积， Ｗ ｏｒｔｍ ａｎｎｉｎ 对此累积有抑制作用，这种抑制作用在一定范围内呈剂量依赖关系（４０～１６０ μｍ ｏｌ／ Ｌ）．结果提示： Ｗ ｏｒｔｍ ａｎｎｉｎ 可能是潜在的抗血小板药物，抑制凝血酶诱导的人血小板聚集主要与其抑制 Ｐ Ｉ Ｐ３ 的累积有关．结果也提示，肌醇磷脂３激酶在血小板活化中起重要作用．
W ortm annin is an irreversible inhibitor of phosphoinositide 3-kinase. Platelet aggregation was assayed by turbidimetry. Phosphoinositide was labeled with 32P-sodium phosphate and extracted with chloroform and methanol. TcL and autoradiography were used to analyze the effect of Wortm annin on thrombin-induced platelet aggregation and Effect of phosphatidylinositol triphosphate (P I P3) accumulation. The results showed that Wortm annin inhibited thrombin (500 U / L) -induced human platelet aggregation in a dose-dependent manner (20-80 μmol / L). Thrombin (500 U / L) induced the accumulation of P I P3 in human platelets, and Wortmannin had a cumulative effect of inhibiting this effect in a dose-dependent manner (40-160 μmol / L). The results suggest that Wortm annin may be a potential anti-platelet drug, and inhibition of thrombin-induced human platelet aggregation is mainly associated with its inhibition of P I P3 accumulation. The results also suggest that inositol phospholipid 3 kinase plays an important role in platelet activation.